Keyphrases
Hepatocellular Carcinoma
53%
Hazard Ratio
42%
Overall Survival
40%
Chronic Hepatitis B
37%
Unresectable Hepatocellular Carcinoma
34%
Transarterial Chemoembolization
32%
Chronic Hepatitis B Patients
32%
Hepatocellular Carcinoma Patients
32%
Hepatitis B e Antigen (HBeAg)
28%
Chemotherapy
21%
HBeAg-negative Chronic Hepatitis B
21%
Sorafenib
20%
Multivariate Analysis
20%
Hepatitis B Surface Antigen (HBsAg)
19%
Taiwan
19%
Nucleos(t)ide Analogues
18%
Intermediate-stage Hepatocellular Carcinoma
18%
HBV-related Hepatocellular Carcinoma
17%
Immune Checkpoint Inhibitors
17%
Alpha-fetoprotein
15%
Hepatocellular Carcinoma Recurrence
15%
Sustained Virological Response
15%
Non-alcoholic Fatty Liver Disease (NAFLD)
14%
Risk Factors
14%
Recurrence-free Survival
14%
Direct-acting Antivirals
13%
Survival Prediction
13%
Viral Load
13%
Nivolumab
12%
Objective Response
12%
Hepatitis B Virus Reactivation
12%
Ropeginterferon alfa-2b
11%
Peginterferon Therapy
11%
Liver Histology
11%
Lenvatinib
11%
Rituximab
11%
CXCL9
11%
Asian Patients
11%
Single-center Experience
11%
Hepatitis
11%
Metallic Stent
11%
Cancer Patients
11%
Chronic Hepatitis C
11%
Propensity Score Analysis
11%
Radiofrequency Ablation
11%
Entecavir
11%
Antiretroviral Therapy
11%
Recurrence Risk
11%
Albumin-bilirubin Grade
10%
Hepatitis B Virus DNA
10%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Chronic Hepatitis B
52%
Hepatitis B Virus
50%
Overall Survival
45%
Hepatitis B(e) Antigen
41%
Recurrent Disease
37%
Hepatitis B Antigen
29%
Sorafenib
20%
Antivirus Agent
19%
Neoplasm
18%
Chemotherapy
18%
Diseases
17%
Immune Checkpoint Inhibitor
17%
Antiviral Therapy
16%
Progression Free Survival
15%
Nivolumab
12%
Recurrence Free Survival
12%
Antiviral Drug
11%
Lenvatinib
11%
Rituximab
11%
Malignant Neoplasm
11%
Chronic Hepatitis C
11%
Entecavir
11%
Tenofovir Disoproxil
10%
Interferon
10%
Liver Fibrosis
9%
Hepatitis B Antibody
8%
Nonalcoholic Fatty Liver
8%
Prevalence
8%
Pembrolizumab
8%
Alpha Fetoprotein
7%
Immunotherapy
7%
Chronic Kidney Failure
6%
Gamma Interferon
6%
Biological Marker
6%
Regorafenib
6%
Peginterferon
6%
Virus DNA
6%
Bilirubin
6%
Abatacept
5%
Yttrium 90
5%
Acetylsalicylic Acid
5%
Cytokine
5%
Biliary Tract Cancer
5%
Fatty Liver
5%
Follicular Lymphoma
5%
Peginterferon Alpha2a
5%
Cohort Study
5%
Tenofovir Alafenamide
5%
Gemcitabine
5%
Medicine and Dentistry
Hepatocellular Carcinoma
73%
Chronic Hepatitis B
34%
Overall Survival
32%
Hepatitis B Virus
31%
Transcatheter Arterial Chemoembolization
28%
Hepatitis B(e) Antigen
25%
Recurrent Disease
18%
Hazard Ratio
17%
Sorafenib
15%
Antiviral Therapy
13%
Nivolumab
11%
Progression Free Survival
11%
Lenvatinib
11%
Nonalcoholic Fatty Liver
11%
Liver Histology
11%
Radiofrequency Ablation
11%
Bilirubin
11%
Multivariate Analysis
10%
Neoplasm
10%
Hepatitis B Antigen
9%
Diseases
8%
Stent Placement
8%
Liver Fibrosis
8%
Pembrolizumab
8%
Recurrence Free Survival
7%
Alpha-Fetoprotein
7%
Obstruction
6%
Prevalence
6%
Liver Cancer
6%
Cancer Staging
6%
Body Mass Index
6%
Systemic Therapy
6%
Pylorus Stenosis
5%
Kidney Function
5%
Propensity Score Matching
5%
Cohort Analysis
5%
Virus Reactivation
5%
Antivirus Agent
5%
Physical Inactivity
5%
Cytokine
5%
COVID-19
5%
Retreatment
5%
Biliary Tract Cancer
5%
Immune Checkpoint Inhibitor
5%
Secondary Prevention
5%
Embolization
5%
Follicular Lymphoma
5%
Yttrium 90
5%
Radioembolization
5%
Rituximab
5%